文献速递神经肌肉病

氯沙米莫德治疗面肩肱型肌营养不良症的安全性与疗效(ReDUX4):一项随机、双盲、安慰剂对照2b期试验

Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.
PubMed 文献 · Lancet Neurol · 2024-01-01

这项在加拿大、法国、西班牙和美国17个神经科中心开展的随机、双盲、安慰剂对照2b期试验纳入80例1型面肩肱型肌营养不良症成人患者,按1:1随机接受口服氯沙米莫德15 mg每日两次或安慰剂治疗48周。主要终点——骨骼肌活检中DUX4驱动基因表达从基线至第16周或第36周的变化——在两组间无显著差异(差值0.43,95%CI -1.04至1.89,p=0.56),氯沙米莫德耐受性良好;作者认为该药与预设结构结局、功能结局及患者自报总体变化印象的潜在改善相关。

要点

  • 主要终点DUX4驱动基因表达变化在氯沙米莫德与安慰剂组间无显著差异
  • 氯沙米莫德耐受性良好,未因不良事件停药,研究期间无死亡
  • 作者认为该药与肌肉脂肪浸润、可达工作空间及患者自报总体变化印象的潜在改善相关

核心结论

  • 尽管氯沙米莫德未显著改变DUX4驱动基因表达,但与安慰剂相比,该药与预设结构结局(肌肉脂肪浸润)、功能结局(可达工作空间,一种肩胛带功能指标)及患者自报总体变化印象的潜在改善相关。
  • 这些发现为氯沙米莫德治疗面肩肱型肌营养不良症成人患者的3期研究的设计和疗效终点选择提供了依据。

研究设计与样本

  • 随机、双盲、安慰剂对照2b期试验,在加拿大、法国、西班牙和美国的17个神经科中心开展。
  • 纳入18-65岁经基因分型确认DUX4表达去抑制的1型面肩肱型肌营养不良症成人患者,Ricci临床严重度评分2-4分,且至少一块骨骼肌经MRI判断适合活检。
  • 2019年8月27日至2020年2月27日共入组80人,按1:1随机分配至口服氯沙米莫德15 mg每日两次组(40人)或安慰剂组(40人),治疗48周。
  • 主要终点为骨骼肌活检样本中DUX4驱动基因表达从基线至第16周或第36周的变化,采用定量RT-PCR测定;主要疗效分析按改良意向治疗原则进行。
  • 研究注册号ClinicalTrials.gov NCT04003974;2b期试验已完成,开放标签延伸研究正在进行。

主要发现

  • 54例(68%)为男性,26例(33%)为女性,70例(88%)为白人,平均年龄45.7岁(SD 12.5)。
  • DUX4驱动基因表达从基线的最小二乘均值变化:氯沙米莫德组0.83(SE 0.61)vs 安慰剂组0.40(SE 0.65),差值0.43(SE 0.56;95%CI -1.04至1.89;p=0.56),两组间无显著差异。
  • 氯沙米莫德组报告29例治疗中出现的不良事件(其中9例与药物相关),安慰剂组报告23例(其中2例与药物相关)。
  • 氯沙米莫德组2例发生研究者判定与氯沙米莫德无关的严重不良事件(酒精中毒和自杀未遂;术后伤口感染),安慰剂组无严重不良事件。
  • 未发生因不良事件导致的治疗中止,研究期间无参与者死亡。

关键数值与推荐

  • 主要疗效终点为骨骼肌活检中DUX4驱动基因表达从基线至第16周或第36周的变化(定量RT-PCR测定)。
  • 氯沙米莫德给药方案为口服15 mg每日两次,疗程48周。
  • 入组标准包括Ricci临床严重度评分2-4分。
  • 主要终点差值0.43(SE 0.56;95%CI -1.04至1.89;p=0.56),未达统计学显著。

临床怎么用

  • 作者认为,尽管主要终点未达显著,氯沙米莫德与预设结构结局、功能结局及患者自报总体变化印象的潜在改善相关,这些发现已用于指导3期研究的设计和疗效终点选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Facioscapulohumeral muscular dystrophy is a hereditary progressive myopathy caused by aberrant expression of the transcription factor DUX4 in skeletal muscle. No approved disease-modifying treatments are available for this disorder. We aimed to assess the safety and efficacy of losmapimod (a small molecule that inhibits p38α MAPK, a regulator of DUX4 expression, and p38β MAPK) for the treatment of facioscapulohumeral muscular dystrophy. METHODS: We did a randomised, double-blind, placebo-controlled phase 2b trial at 17 neurology centres in Canada, France, Spain, and the USA. We included adults aged 18-65 years with type 1 facioscapulohumeral muscular dystrophy (ie, with loss of repression of DUX4 expression, as ascertained by genotyping), a Ricci clinical severity score of 2-4, and at least one skeletal muscle judged using MRI to be suitable for biopsy. Participants were randomly allocated (1:1) to either oral losmapimod (15 mg twice a day) or matching placebo for 48 weeks, via an interactive response technology system. The investigator, study staff, participants, sponsor, primary outcome assessors, and study monitor were masked to the treatment allocation until study closure. The primary endpoint was change from baseline to either week 16 or 36 in DUX4-driven gene expression in skeletal muscle biopsy samples, as measured by quantitative RT-PCR. The primary efficacy analysis was done in all participants who were randomly assigned and who had available data for assessment, according to the modified intention-to-treat principle. Safety and tolerability were assessed as secondary endpoints. This study is registered at ClinicalTrials.gov, number NCT04003974. The phase 2b trial is complete; an open-label extension is ongoing. FINDINGS: Between Aug 27, 2019, and Feb 27, 2020, 80 people were enrolled. 40 were randomly allocated to losmapimod and 40 to placebo. 54 (68%) participants were male and 26 (33%) were female, 70 (88%) were White, and mean age was 45·7 (SD 12·5) years. Least squares mean changes from baseline in DUX4-driven gene expression did not differ significantly between the losmapimod (0·83 [SE 0·61]) and placebo (0·40 [0·65]) groups (difference 0·43 [SE 0·56; 95% CI -1·04 to 1·89]; p=0·56). Losmapimod was well tolerated. 29 treatment-emergent adverse events (nine drug-related) were reported in the losmapimod group compared with 23 (two drug-related) in the placebo group. Two participants in the losmapimod group had serious adverse events that were deemed unrelated to losmapimod by the investigators (alcohol poisoning and suicide attempt; postoperative wound infection) compared with none in the placebo group. No treatment discontinuations due to adverse events occurred and no participants died during the study. INTERPRETATION: Although losmapimod did not significantly change DUX4-driven gene expression, it was associated with potential improvements in prespecified structural outcomes (muscle fat infiltration), functional outcomes (reachable workspace, a measure of shoulder girdle function), and patient-reported global impression of change compared with placebo. These findings have informed the design and choice of efficacy endpoints for a phase 3 study of losmapimod in adults with facioscapulohumeral muscular dystrophy. FUNDING: Fulcrum Therapeutics.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Tawil R, Wagner KR, Hamel JI, et al. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 2024. PMID: 38631764. doi:10.1016/S1474-4422(24)00073-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。